Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway

Ibrutinib, a bruton tyrosine kinase (BTK) inhibitor which suppresses B-cell receptor signaling, has remarkably improved the outcome of patients with mantle cell lymphoma (MCL). However, approximately 33% of MCL patients have primary Ibrutinib resistance, and acquired Ibrutinib resistance is nearly u...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ye, Lu, Peng, Zhou, Yan, Zhang, Lifei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2021
Materias:
Biochemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686732/
https://www.ncbi.nlm.nih.gov/pubmed/35003920
http://dx.doi.org/10.7717/peerj.12571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686732/
https://www.ncbi.nlm.nih.gov/pubmed/35003920
http://dx.doi.org/10.7717/peerj.12571

Ejemplares similares